Larimar Therapeutics Inc (LRMR)

01:50 AM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc.LRMR - PR Newswire

01:50 AM

11:48 AM

Multi factor analysis applied to Larimar Therapeutics Inc.2025 Price Momentum & Community Driven Trade Alerts - newser.com

11:48 AM

10:38 AM

Is Larimar Therapeutics Inc. stock poised for growthQuarterly Profit Summary & High Accuracy Investment Entry Signals - newser.com

10:38 AM

07:57 AM

Real time breakdown of Larimar Therapeutics Inc. stock performanceQuarterly Profit Report & Risk Managed Investment Strategies - newser.com

07:57 AM

Oct 10, 2025

Larimar Therapeutics (NASDAQ:LRMR) Given Sell (D-) Rating at Weiss Ratings - MarketBeat

Oct 10, 2025

Oct 10, 2025

Intraday pattern recognizer results for Larimar Therapeutics Inc.2025 Buyback Activity & Consistent Profit Focused Trading Strategies - newser.com

Oct 10, 2025

Oct 10, 2025

How to forecast Larimar Therapeutics Inc. trends using time seriesQuarterly Profit Review & Stock Portfolio Risk Control - newser.com

Oct 10, 2025

Oct 10, 2025

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World

Oct 10, 2025

Oct 09, 2025

Volatility clustering patterns for Larimar Therapeutics Inc.July 2025 PostEarnings & Free Real-Time Volume Trigger Notifications - newser.com

Oct 09, 2025

Oct 09, 2025

What MACD and RSI say about Larimar Therapeutics Inc.Trade Ideas & Verified Stock Trade Ideas - newser.com

Oct 09, 2025

Oct 09, 2025

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Oct 09, 2025

Oct 09, 2025

How Larimar Therapeutics Inc. (ZA71) stock compares with top peersMarket Trend Review & High Conviction Buy Zone Alerts - newser.com

Oct 09, 2025

Oct 07, 2025

Larimar announces 25 mg, 50 mg data from OL study of nomlabofusp - MSN

Oct 07, 2025

Oct 06, 2025

Citizens JMP Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛

Oct 06, 2025

Oct 06, 2025

Why Larimar Therapeutics Inc. (ZA71) stock fits value portfoliosDip Buying & Short-Term Trading Alerts - newser.com

Oct 06, 2025

Oct 06, 2025

Using Python tools to backtest Larimar Therapeutics Inc. strategiesJuly 2025 Pullbacks & Risk Adjusted Buy/Sell Alerts - newser.com

Oct 06, 2025

Oct 06, 2025

Can you recover from losses in Larimar Therapeutics Inc.2025 Price Momentum & Risk Controlled Stock Alerts - newser.com

Oct 06, 2025

Oct 05, 2025

Larimar Reports Positive Long-Term Data on Nomlabofusp in Friedreich’s Ataxia - MyChesCo

Oct 05, 2025

Oct 05, 2025

What’s next for Larimar Therapeutics Inc. stock priceEarnings Overview Report & Accurate Technical Buy Alerts - newser.com

Oct 05, 2025

Oct 05, 2025

Market reaction to Larimar Therapeutics Inc.’s recent newsWeekly Trend Report & Proven Capital Preservation Tips - newser.com

Oct 05, 2025

Oct 04, 2025

What analysts say about Larimar Therapeutics Inc stockDouble Top/Bottom Patterns & Low Risk Trading Portfolio - earlytimes.in

Oct 04, 2025

Oct 04, 2025

Will Positive Nomlabofusp Study Results Alter Larimar Therapeutics' (LRMR) Standing in Rare Disease Treatment? - Yahoo Finance

Oct 04, 2025

Oct 03, 2025

Why Larimar Therapeutics (LRMR) Is Up After Positive Long-Term Results for Friedreich's Ataxia Therapy - Sahm

Oct 03, 2025

Oct 03, 2025

Larimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $21.00 by Analysts at Oppenheimer - Defense World

Oct 03, 2025

Oct 03, 2025

Why ETFs are accumulating Larimar Therapeutics Inc. (ZA71) stockDividend Hike & Real-Time Stock Movement Alerts - newser.com

Oct 03, 2025

Oct 03, 2025

Is Larimar Therapeutics Inc. (ZA71) stock worth buying before Fed actionJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com

Oct 03, 2025

Oct 02, 2025

Oppenheimer Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq

Oct 02, 2025

Oct 02, 2025

Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛

Oct 02, 2025

Oct 02, 2025

Oppenheimer Lowers Larimar Therapeutics (LRMR) Price Target to $21 | LRMR Stock News - GuruFocus

Oct 02, 2025

Oct 02, 2025

Equities Analysts Issue Forecasts for LRMR FY2027 Earnings - MarketBeat

Oct 02, 2025

Oct 01, 2025

Is now a turning point for Larimar Therapeutics Inc.2025 Technical Overview & High Accuracy Trade Alerts - newser.com

Oct 01, 2025

Oct 01, 2025

What analysts say about CTVA stockCandlestick Pattern Analysis & Rapid Capital Appreciation - earlytimes.in

Oct 01, 2025

Oct 01, 2025

Baird Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $7 - 富途牛牛

Oct 01, 2025

Sep 30, 2025

Wedbush Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq

Sep 30, 2025

Sep 30, 2025

Anaphylaxis drives Larimar’s setback, weak efficacy behind MoonLake’s: Clinical Report - biocentury.com

Sep 30, 2025

Sep 30, 2025

Navigating Larimar’s Anaphylaxis Storm: Robust FA Data Presents Risk-Reward Opportunity (NASDAQ:LRMR) - Seeking Alpha

Sep 30, 2025

Sep 30, 2025

LRMR Analyst Rating Update: Price Target Lowered by Wedbush | LR - GuruFocus

Sep 30, 2025

Sep 30, 2025

Larimar Therapeutics (NASDAQ:LRMR) Given New $11.00 Price Target at Wedbush - MarketBeat

Sep 30, 2025

Sep 30, 2025

LRMR: Baird Maintains Rating but Lowers Price Target to $7.00 | - GuruFocus

Sep 30, 2025

Sep 30, 2025

Wedbush Cuts Price Target on Larimar Therapeutics to $11 From $15, Keeps Outperform Rating - MarketScreener

Sep 30, 2025

Sep 30, 2025

Baird Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq

Sep 30, 2025

Sep 29, 2025

Larimar Therapeutics stock price target lowered to $7 at Jones Trading - Investing.com Canada

Sep 29, 2025

Sep 29, 2025

Larimar Proceeding Toward Accelerated Approval Filing In Friedreich’s Ataxia - insights.citeline.com

Sep 29, 2025